Immuron New U.S. Department of Defense Award & Clinical Trial Update
(NASDAQ:IMRN),(AUST:IMC.AX), Highlights: New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and Shigella Uniformed Services University P2TD clinical study update MELBOURNE, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, announces a new research agreement with the Naval […]